{"title":"Regorafenib or Cabozantinib in second or subsequent lines after Sorafenib in advanced hepatocellular carcinoma. Which way to chose?","authors":"J. Giuliani, F. Fiorica, A. Bonetti","doi":"10.15761/ICST.1000344","DOIUrl":null,"url":null,"abstract":"The aim of this paper is to assess the cost-effectivess of regorafenib and cabozantib in the treatment of advanced hepatocellular carcinoma (HCC) after sorafenib. Pivotal phase III randomized controlled trials (RCTs) were considered. Incremental cost-effectiveness ratio (ICER) was calculated for both treatments. Two phase III RCTs, including 1274 patients, were considered. Regorafenib resulted the less expensive, with 2771 € per month overall survival (OS)-gained versus 5309 € of cabozantinib. Combining pharmacological costs of drugs with the measure of efficacy represented by the OS, regorafenib is a cost-effective for the treatment of advanced HCC after sorafenib.","PeriodicalId":90850,"journal":{"name":"Integrative cancer science and therapeutics","volume":"43 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2020-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Integrative cancer science and therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.15761/ICST.1000344","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
The aim of this paper is to assess the cost-effectivess of regorafenib and cabozantib in the treatment of advanced hepatocellular carcinoma (HCC) after sorafenib. Pivotal phase III randomized controlled trials (RCTs) were considered. Incremental cost-effectiveness ratio (ICER) was calculated for both treatments. Two phase III RCTs, including 1274 patients, were considered. Regorafenib resulted the less expensive, with 2771 € per month overall survival (OS)-gained versus 5309 € of cabozantinib. Combining pharmacological costs of drugs with the measure of efficacy represented by the OS, regorafenib is a cost-effective for the treatment of advanced HCC after sorafenib.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
